Industry news

FDA panel backs Pfizer biosim to blockbuster anemia meds from Amgen, Johnson & Johnson

Eric Sagonowsky / FiercePharma

Pfizer’s biosimilar to blockbuster anemia meds Epogen and Procrit won the support of an FDA expert panel on Thursday, moving another step closer to a potential approval.

Less promo, more info: Annual physician poll finds docs want fewer pharma ads, more education

Beth Snyder Bulik / FiercePharmaMarketing

Enough with the online ads, pharma. That’s one of the key finding from doctors who participated in Manhattan Research's annual "Taking the Pulse" study of physician technology use and attitudes, now in its 15th year.

Drug approvals bounce back as R&D labs churn out new winners

Ben Hirschler / Reuters

The number of new drugs approved for sale in United States and Europe has bounced back this year, suggesting a marked slowdown in 2016 was an aberration rather than a sign of flagging research and development productivity.

Kazakhstan sets fixed prices for 105 medicinal products and medical devices

GMP News

The Memorandum became effective on May 23, 2017 and will be valid until the end of this year. The document was signed by the heads of leading pharmaceutical associations of Kazakhstan, including the Association for Support and Development of Pharmaceutical Activities of the Republic of Kazakhstan, Association of International Pharmaceutical Manufacturers in Kazakhstan, Association of Pharmaceutical Distributors of the Republic of Kazakhstan, Association PharmMedIndustry of Kazakhstan.

Russia is establishing a competitive rehabilitation industry

GMP News

The Russian Ministry of Industry and Trade has prepared a draft Strategy for Developing the Manufacturing of Rehabilitation-Oriented Industrial Products until 2025.

24 May 2017

Syndax Prices Public Offering of Common Stock

Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a price to the public of $13.25 per share. The gross proceeds to Syndax from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $49.7 million. The offering is expected to close on May 31, 2017, subject to customary closing conditions.

Russia's Pharmacy Chain sees online sales accounting for 10 percent of total by mid-2018

Anna Pruchnicka and Anna Rzhevkina / Reuters

Russian health and beauty products retailer Pharmacy Chain 36.6 expects online sales to account for 10 percent of total revenue by mid-2018 from just 1 percent now, its corporate finance director said.

23 May 2017

Syndax Announces Proposed Public Offering of Common Stock

Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Syndax also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares sold in the public offering. All of the shares in the proposed offering are to be sold by Syndax.

European Medicines Agency issued its 2016 annual report

GMP News

The European Medicines Agency (EMA) published 2016 annual report. It focuses on the Agency’s key achievements in the areas of medicine evaluation, support to research and development of new and innovative treatments and the safety monitoring of medicines in real life.

Key growth drivers of Russian pharmaceutical retail run out of steam

GMP News

On the one hand, in Q1 2017, Russian pharmaceutical retail sector strengthened the positive trends of the past year. The demand for medicinal products is recovering, albeit slowly, both as a result of higher consumption in terms of physical volume and the shift of consumers to more expensive drugs. On the other hand, current positive trends are so far, alas, just a pleasant fact which, while making the retail pharmacies feel better in general, cannot serve, for a number of objective reasons, as a foundation for either quantitative or qualitative development of the industry.